Over the past 3 months, 13 analysts have published their opinion on CRISPR Therapeutics CRSP stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

According to 13 analyst offering 12-month price targets in the last 3 months, CRISPR Therapeutics has an average price target of $68.46 with a high of $88.00 and a low of $42.00.

Below is a summary of how these 13 analysts rated CRISPR Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This average price target has increased by 8.67% over the past month.

Stay up to date on CRISPR Therapeutics analyst ratings.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.